What is CRISPR Therapeutics AG 3-Year Share Buyback Ratio?
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. CRISPR Therapeutics AG's current 3-Year Share Buyback Ratio was -3.70%.
The historical rank and industry rank for CRISPR Therapeutics AG's 3-Year Share Buyback Ratio or its related term are showing as below:
CRSP'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -22.1 Med: -9.1 Max: -0.7
Current: -3.7
During the past 11 years, CRISPR Therapeutics AG's highest 3-Year Share Buyback Ratio was -0.70%. The lowest was -22.10%. And the median was -9.10%.
CRSP's 3-Year Share Buyback Ratio is ranked better than 69.44% of 1263
companies
in the Biotechnology industry
Industry Median: -9.8
vs CRSP: -3.70
Competitive Comparison of CRISPR Therapeutics AG's 3-Year Share Buyback Ratio
For the Biotechnology subindustry, CRISPR Therapeutics AG's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's 3-Year Share Buyback Ratio falls into.
CRISPR Therapeutics AG 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
CRISPR Therapeutics AG (NAS:CRSP) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
CRISPR Therapeutics AG 3-Year Share Buyback Ratio Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your